ClinicalTrials.gg
RecruitingNCT05093881Updated Sep 21, 2026

Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC

An observational study in Alcoholic Liver Cirrhosis, sponsored by Pharmicell Co., Ltd.. Recruiting at 14 sites in South Korea. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Pharmicell Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
19 Years to 70 Years
Sex
All
01

Study summary

The goal of this observational study is to learn about the long-term safety of Cellgram-LC in patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 study.

The main question it aims to answer is:

- Do adverse event of special interest (AESI) or liver transplantation occur during the 5 years after Cellgram-LC administration?

Participants who previously received Cellgram-LC in the PMC-P-07 study and voluntarily consent to participate in this long-term follow-up study will be followed for 5 years after Cellgram-LC administration through telephone visits to collect information on AESI and liver transplantation.

02

Conditions studied

  • Alcoholic Liver Cirrhosis

Keywords

  • Cellgram-LC
  • Long-Term Follow-up
  • Adverse Events of Special Interest
  • Liver Transplantation
  • Autologous Bone Marrow-Derived Mesenchymal Stem Cell
  • Mesenchymal Stem Cell
03

In context

Liver Cirrhosis, Alcoholic

45 studies on the registry are indexed under Liver Cirrhosis, Alcoholic; 14 are open to participants now.

This study's planned enrollment of 100 is below the median of 142 across 19 observational studies indexed under Liver Cirrhosis, Alcoholic.

Browse Liver Cirrhosis, Alcoholic studies →

Lead sponsor

Pharmicell Co., Ltd. is the lead sponsor of 18 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 clinical trial and voluntarily consent to participate in this long-term follow-up study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who received Cellgram-LC in the PMC-P-07 clinical trial.
  2. Participants who voluntarily provide written to participate in this study.

Exclusion criteria

Exclusion Criteria:

- None.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cellgram-LC-treated Participants

    Participants who previously received Cellgram-LC in the PMC-P-07 study and voluntarily provide written informed consent to participate in this long-term follow-up study.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Event of Special Interest (AESI)

    Adverse event of special interest (AESI) include death, neoplasm or malignancy in any tissue or organ, immune reactions including worsening of pre-existing autoimmune disease or new-onset autoimmune disease, and other delayed adverse events considered related to Cellgram-LC.

    Time frame: From the date of Cellgram-LC administration through 5 years after administration, assessed annually.

  2. Occurrence of Liver Transplantation

    The number and percentage of participants who undergo liver transplantation will be summarized during the 5-year follow-up period after Cellgram-LC administration.

    Time frame: From the date of Cellgram-LC administration through 5 years after administration, assessed annually.

07

Study locations

12 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2021
First posted
Oct 26, 2021
StartActual
Sep 9, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2031
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05093881
Lead sponsor
Pharmicell Co., Ltd.
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Sep 9, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Sep 21, 2026

Study contacts

YUJEONG KIM
Contact
yjkim@pharmicell.com
82-2-3496-0137
Moonyoung Kim
principal investigator · Wonju Severance Christian Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion